Encyclopedia of contested claims
The evidence generally suggests that SSRIs can reduce depressive symptoms more than placebo on average, but the size of the added benefit for moderate depression is often modest and varies by patient, trial design, medication, and outcome measure.
8 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its full review of this claim. This draft summarizes key issues likely to matter in the assessment, including randomized trial evidence, meta-analyses, clinical guideline positions, placebo response, symptom severity, functional outcomes, and patient-level variation.
The evidence generally suggests that SSRIs can reduce depressive symptoms more than placebo on average, but the size of the added benefit for moderate depression is often modest and varies by patient, trial design, medication, and outcome measure.
The claim asks whether selective serotonin reuptake inhibitors, or SSRIs, are more effective than placebo for people with moderate depression. SSRIs include commonly prescribed medicines such as sertraline, fluoxetine, escitalopram, citalopram, paroxetine, and fluvoxamine.
The most direct evidence for this question comes from randomized controlled trials comparing an SSRI with an inactive placebo. These studies often measure changes in depression rating scales over several weeks, such as the Hamilton Depression Rating Scale or the Montgomery-Asberg Depression Rating Scale.
A key issue is what counts as “more effective.” A medicine may show an average statistical advantage over placebo while producing a smaller difference than some patients would consider clinically meaningful. The answer can also differ depending on whether the outcome is symptom score improvement, remission, response rate, relapse prevention, functioning, quality of life, or adverse effects.
Large reviews and meta-analyses generally find that antidepressants, including SSRIs, perform better than placebo on average in acute major depression trials. The estimated advantage is usually larger in more severe depression and smaller in milder presentations.
For moderate depression, the picture is mixed because trial populations, definitions of severity, and outcome thresholds vary. Some analyses report a measurable average SSRI-placebo difference, while others emphasize that the absolute benefit may be modest and that many participants improve in both treatment and placebo groups.
Clinical guidelines typically do not treat SSRIs as the only appropriate first-line option for moderate depression. Many recommend shared decision-making among antidepressant medication, psychotherapy, guided self-help, lifestyle and social interventions, or combined treatment depending on symptom burden, patient preference, prior treatment response, risk, access, and comorbidities.
Harms and tolerability are part of the benefit assessment. SSRIs can cause side effects such as nausea, sleep disturbance, sexual dysfunction, emotional blunting, activation, and discontinuation symptoms. For an individual patient with moderate depression, the net value of an SSRI depends on both the likelihood of benefit and the likelihood and importance of adverse effects.
Moderate depression is not a single uniform condition. People grouped under this label may differ in episode duration, recurrence, anxiety symptoms, suicidality, psychosocial stressors, medical comorbidities, and prior treatment history, all of which may affect outcomes.
Many placebo-controlled antidepressant trials are relatively short and may exclude patients with complex real-world presentations. Publication bias, selective outcome reporting, high placebo response, and unblinding due to side effects can also complicate interpretation.
The most useful future evidence would better identify which patients with moderate depression are most likely to experience meaningful improvement from SSRIs compared with placebo or non-drug options, and how benefits compare with harms over longer follow-up.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | No · 78% | No · 63% | No · 72% | No · 90% |
| OpenAI GPT-5.4 | No · 78% | No · 63% | No · 72% | No · 90% |
| Mistral Medium 3.5 | No · 78% | No · 63% | No · 72% | No · 90% |
| Llama 4 Maverick | No · 78% | No · 63% | No · 72% | No · 90% |
| Gemini 3.1 Pro | — | — | — | Incomplete |
| Claude Opus 4.7 | No · 78% | No · 63% | No · 72% | No · 90% |
| GLM 5.1 | No · 78% | No · 63% | No · 72% | No · 90% |
| DeepSeek V4 Pro | No · 78% | No · 63% | No · 72% | No · 90% |
| Qwen 3.7 Max | No · 78% | No · 63% | No · 72% | No · 90% |
| Kimi K2.6 | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
SSRIs show a statistically significant average benefit over placebo in reducing depressive symptom scores in randomized trials of moderate depression, though the added effect is typically modest (often around 2...
Probably yes, but with an important qualifier: SSRIs are on average more effective than placebo in acute treatment trials of adult major depression, including patients with moderate severity, yet the extra bene...
SSRIs are more effective than placebo for moderate depression on average, but the magnitude of benefit is often modest and may not be clinically meaningful for all patients. The first sub-claim is supported by...
SSRIs are more effective than placebo for moderate depression on average, but the size of the added benefit is often modest. The confidence in this assessment is moderate. Key evidence includes a patient-level...
Incomplete response: output limit reached before the answer finished.
Yes, SSRIs are more effective than placebo for moderate depression on average, but the added benefit is typically modest and its clinical meaningfulness for any individual patient is debated. Confidence: Modera...
Yes, SSRIs are more effective than placebo for moderate depression, but the magnitude of the added benefit is modest and its clinical significance varies among patients. Confidence: High. Key evidence: The Lanc...
Yes, SSRIs are more effective than placebo for moderate depression on average, but the added benefit is often modest and may not be clinically meaningful for many patients. The evidence supports a statistically...
SSRIs are statistically more effective than placebo for moderate depression on average, but the magnitude of this added benefit is modest, and its clinical significance for moderate depression specifically is h...
